Clinical Trial Detail

NCT ID NCT02039674
Title A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel + Pembrolizumab

Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Pemetrexed Disodium

Ipilimumab + Pembrolizumab

Erlotinib + Pembrolizumab

Gefitinib + Pembrolizumab

Age Groups: adult

No variant requirements are available.